Journal of Pediatric Nursing
Volume 24, Issue 5 , Pages 433-440 , October 2009

Uncertainties and Anxieties about Vaccination, Answering Parent's Concerns

References 

  1. Anderson RM. Infectious diseases of humans. Oxford: Oxford University Press; 1991;
  2. Baker JP. The pertussis vaccine controversy in Great Britain, 1974–1986. Vaccine. 2003;21:4003–4010
  3. Bellaby P. Communication and miscommunication of risk: Understanding UK parents' attitudes to combined MMR vaccination. BMJ. 2003;327:725–728
  4. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112:815–820
  5. Bonhoeffer J, Kohl K, Chen R, Duclos P, Heijbel H, Heininger U, et al. The Brighton Collaboration: Addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine. 2002;21:298–302
  6. Bradford Hill A. The environment and disease: Association or causation?. Proceedings of the Royal Society of Medicine. 1965;58:295–300
  7. Carrat F, Flahault A. Influenza vaccine: The challenge of antigenic drift. Vaccine. 2007;25:6852–6862
  8. CDC . Epidemiology and prevention of vaccine-preventable diseases. 10th ed.. Washington, DC: Public Health Foundation; 2008;
  9. DoH . Immunisation against infectious diseases. London: Department of Health; 2006;
  10. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines?. Vaccine. 2007;25:5945–5957
  11. Evans G. Vaccine injury compensation programs worldwide. Vaccine. 1999;17(Supplement 3):S25–S35
  12. FDA . Guidance for industry for the evaluation of combination vaccines for preventable diseases: Production, testing and clinical studies. Rockville, MD: Food and Drug Administration; 1997;
  13. Freed GL. Lessons from across the pond: What the US can learn from European immunization programs. Vaccine. 2007;25:6148–6157
  14. Halsey NA. Combination vaccines: Defining and addressing current safety concerns. Clinical Infectious Diseases. 2001;33(s4):S312–S318
  15. Halsey NA. The science of evaluation of adverse events associated with vaccination. Seminars in Pediatric Infectious Diseases. 2002;13:205–214
  16. Haynes B. Can it work? Does it work? Is it worth it?. BMJ. 1999;319:652–653
  17. Hilton S, Petticrew M, Hunt K. ‘Combined vaccines are like a sudden onslaught to the body's immune system’: Parental concerns about vaccine ‘overload’ and ‘immune-vulnerability’. Vaccine. 2006;24:4321–4327
  18. Hudgens MG, Gilbert PB, Self SG. Endpoints in vaccine trials. Statistical Methods in Medical Research. 2004;13:89–114
  19. Isaacs D. Should Australia introduce a vaccine injury compensation scheme?. Journal of Paediatrics and Child Health. 2004;40:247–249
  20. Jacobson RM, Poland GA. The genetic basis for measles vaccine failure. Acta Paediatrica. 2004;93(s445):43–46
  21. Khakoo GA, Lack G. Recommendations for using MMR vaccine in children allergic to eggs. British Medical Journal. 2000;320:929–932
  22. Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Archives of Disease in Childhood. 2008;93:665–669
  23. Lucas RN, McMichael AJ. Association or causation: Evaluating links between “environment and disease”. Bulletin of the World Health Organisation. 2005;83:792–795
  24. McBrien J, Murphy J, Gill D, Cronin M, O'Donovan C, Cafferkey MT. Measles outbreak in Dublin, 2000. Pediatric Infectious Disease Journal. 2003;22:580–584
  25. Murch SH, Anthony A, Casson DH, Malik M, Berelowitz M, Dhillon AP, et al. Retraction of an interpretation. Lancet. 2004;363:750
  26. Offit PA, Jew RK. Addressing parents' concerns: Do vaccines contain harmful preservatives, adjuvants, additives, or residuals?. Pediatrics. 2003;112:1394–1397
  27. Offit PA, Moser CA. The problem with Dr Bob's alternative vaccine schedule. Pediatrics. 2009;123:e164–e169
  28. Offit PA, Quarles J, Gerber MA, Hackett CJ, Marcuse EK, Kollman TR, et al. Addressing parents' concerns: Do multiple vaccines overwhelm or weaken the infant's immune system?. Pediatrics. 2002;109:124–129
  29. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: A critical review of published original data. Pediatrics. 2004;114:793–804
  30. Petousis-Harris H. Vaccine injection technique and reactogenicity—Evidence for practice. Vaccine. 2008;26:6299–6304
  31. Pichichero ME, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: A descriptive study. Lancet. 2002;360:1737–1741
  32. Plotkin SA. Vaccines: Correlates of vaccine-induced immunity. Clinical Infectious Diseases. 2008;47:401–409
  33. Rennels MB. The rotavirus vaccine story: A clinical investigator's view. Pediatrics. 2000;106:123–125
  34. Sengupta N, Booy R, Schmitt H, Peltola H, Van-Damme P, Schumacher R, et al. Varicella vaccination in Europe: Are we ready for a universal childhood programme?. European Journal of Pediatrics. 2008;167:47–55
  35. Siegrist C-A. Neonatal and early life vaccinology. Vaccine. 2001;19:3331–3346
  36. Smeeth L, Rodrigues LC, Hall AJ, Fombonne E, Smith PG. Evaluation of adverse effects of vaccines: The case-control approach. Vaccine. 2002;20:2611–2617
  37. Tapiainen T, Cherry JD, Heininger U. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria–tetanus–pertussis vaccines in infants. Vaccine. 2005;23:5106–5112
  38. Tozzi AE. Field evaluation of vaccine safety. Vaccine. 2004;22:2091–2095
  39. Vidor E. The nature and consequences of intra- and inter-vaccine interference. Journal of Comparative Pathology. 2007;137(Supplement 1):S62–S66
  40. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, et al. Ileal–lymphoid–nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet. 1998;351:637–641
  41. WHO . Operational targets for EPI diseases. Copenhagen: WHO Regional Office for Europe; 1996;
  42. WHO . State of the world's vaccines and immunization. Geneva: World Health Organization; 2003;
  43. WHO . Guidelines on clinical evaluation of vaccines: Regulatory expectations. Fifty-second report. Annexe 1. Geneva: World Health Organization; 2004;
  44. WHO . Guidelines on nonclinical evaluation of vaccines WHO Technical Report Series No. 927, Annex 1. Geneva: World Health Organisation; 2005;

PII: S0882-5963(09)00122-5

doi: 10.1016/j.pedn.2009.03.002

Journal of Pediatric Nursing
Volume 24, Issue 5 , Pages 433-440 , October 2009

Article Tools